Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

ondansetron

ondansetron
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Zuplenz DISINTEGRATING STRIP, ORAL 4 mg, 8 mg    
Zofran SOLUTION, INJECTABLE 2 mg/mL      
Zofran SOLUTION, ORAL 4 mg/5 mL      
Zofran ODT TABLET, DISINTEGRATING, ORAL 4 mg, 8 mg      
Zofran TABLET, ORAL 4 mg, 8 mg      
VIEW MORE 5-HT3 Receptor Antagonists
CLASS
562220
Comments:

ORDERED FORMULATION

FORMULARY INTERCHANGE

ondansetron (Zuplenz)

  • 4 mg disintegrating strip oral
  • 8 mg disintegrating strip oral

ondansetron (Zofran ODT)

  • 4 mg disintegrating tablet oral
  • 8 mg disintegrating tablet oral

Due to potential risk of QT interval prolongation, IV doses should not exceed 16 mg. HH P&T has approved limiting both parenteral and oral single doses to a maximum of 16 mg. Reviewed: January 27, 2015

Standardize piggyback solution to 50 mL NS

Reviewed: January 23, 2007, March 27, 2007 and September 23, 2008 (Ondansetron ODT) and December 14, 2010 (ZUPLENZ and January 22, 2013 (ondansetron ODT)

Last updated: Jun. 29, 2017






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved